Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH

Neuroscience Letters

Volumn 533, Issue 1, 2013, Pages 96-99

  Killick, R ^a   Hughes, T R ^b   Morgan, B P ^b   Lovestone, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's; CFH; CR1; Crry; Sporadic; Tau

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT RECEPTOR 1; COMPLEMENT FACTOR H; CR1 PROTEIN; CRRY PROTEIN; RECEPTOR; SERINE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DISEASE COURSE; GENE DELETION; GENETIC ASSOCIATION; HIPPOCAMPUS; IMMUNOBLOTTING; MOUSE; NEUROPATHOLOGY; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC ALZHEIMER DISEASE;

ALZHEIMER DISEASE; ANIMALS; COMPLEMENT FACTOR H; HIPPOCAMPUS; HUMANS; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; RECEPTORS, COMPLEMENT; RECEPTORS, COMPLEMENT 3B; TAU PROTEINS;

EID: 84871680169     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.11.008     Document Type: Article

References (37)

1. Alonso A.C., Grundke-Iqbal I., Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nature Medicine 1996, 2:783-787.
2. Alonso Adel C., Mederlyova A., Novak M., Grundke-Iqbal I., Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. Journal of Biological Chemistry 2004, 279:34873-34881.
3. Biernat J., Gustke N., Drewes G., Mandelkow E.M., Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11:153-163.
4. Brouwers N., Cauwenberghe C.V., Engelborghs S., Lambert J.C., Bettens K., Bastard N.L., Pasquier F., Montoya A.G., Peeters K., Mattheijssens M., Vandenberghe R., Deyn P.P., Cruts M., Amouyel P., Sleegers K., Broeckhoven C.V. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Molecular Psychiatry 2012, 17:223-233.
5. Brunden K.R., Trojanowski J.Q., Lee V.M. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nature Reviews Drug Discovery 2009, 8:783-793.
6. Bu G. ApoE and apoE receptors in brain lipid metabolism and AD. Molecular Neurodegeneration 2012, 7(Suppl. 1):L10.
7. Cho J.H., Johnson G.V. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. Journal of Neurochemistry 2004, 88:349-358.
8. Crehan H., Holton P., Wray S., Pocock J., Guerreiro R., Hardy J. Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology 2012, 217:244-250.
9. Emmerling M.R., Watson M.D., Raby C.A., Spiegel K. The role of complement in Alzheimer's disease pathology. Biochimica et Biophysica Acta 2000, 1502:158-171.
10. Fingeroth J.D., Benedict M.A., Levy D.N., Strominger J.L. Identification of murine complement receptor type 2. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:242-246.
11. Goedert M., Jakes R., Crowther R.A., Cohen P., Vanmechelen E., Vandermeeren M., Cras P. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochemical Journal 1994, 301(Pt 3):871-877.
12. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. Journal of Neurochemistry 2009, 110:1129-1134.
13. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends in Pharmacological Sciences 1991, 12:383-388.
14. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., Van Den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics 2009, 41:1088-1093.
15. Hu X., Pickering E., Liu Y.C., Hall S., Fournier H., Katz E., Dechairo B., John S., Van Eerdewegh P., Soares H. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS ONE 2011, 6:e16616.
16. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
17. Killick R., Scales G., Leroy K., Causevic M., Hooper C., Irvine E.E., Choudhury A.I., Drinkwater L., Kerr F., Al-Qassab H., Stephenson J., Yilmaz Z., Giese K.P., Brion J.P., Withers D.J., Lovestone S. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochemical and Biophysical Research Communications 2009, 386:257-262.
18. Kinoshita T., Takeda J., Hong K., Kozono H., Sakai H., Inoue K. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. Journal of immunology 1988, 140:3066-3072.
19. Kurtz C.B., O'Toole E., Christensen S.M., Weis J.H. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. Journal of Immunology 1990, 144:3581-3591.
20. Kurtz C.B., Paul M.S., Aegerter M., Weis J.J., Weis J.H. Murine complement receptor gene family. II. Identification and characterization of the murine homolog (Cr2) to human CR2 and its molecular linkage to Crry. Journal of Immunology 1989, 143:2058-2067.
21. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics 2009, 41:1094-1099.
22. Molina H., Kinoshita T., Inoue K., Carel J.C., Holers V.M. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. Journal of Immunology 1990, 145:2974-2983.
23. Molina H., Wong W., Kinoshita T., Brenner C., Foley S., Holers V.M. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. Journal of Experimental Medicine 1992, 175:121-129.
24. Morgan K. The three new pathways leading to Alzheimer's disease. Neuropathology and Applied Neurobiology 2011, 37:353-357.
25. Necula M., Kuret J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. Journal of Biological Chemistry 2004, 279:49694-49703.
26. Pramoonjago P., Takeda J., Kim Y.U., Inoue K., Kinoshita T. Ligand specificities of mouse complement receptor types 1 (CR1) and 2 (CR2) purified from spleen cells. International Immunology 1993, 5:337-343.
27. Preuss U., Doring F., Illenberger S., Mandelkow E.M. Cell cycle-dependent phosphorylation and microtubule binding of tau protein stably transfected into Chinese hamster ovary cells. Molecular Biology of the Cell 1995, 6:1397-1410.
28. Quigg R.J., Morgan B.P., Holers V.M., Adler S., Sneed A.E., Lo C.F. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney International 1995, 48:412-421.
29. Ramaglia V., Hughes T.R., Donev R.M., Ruseva M.M., Wu X., Huitinga I., Baas F., Neal J.W., Morgan B.P. C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:965-970.
30. Ruseva M.M., Hughes T.R., Donev R.M., Sivasankar B., Pickering M.C., Wu X., Harris C.L., Morgan B.P. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Molecular Immunology 2009, 46:803-811.
31. Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Archives of Biochemistry and Biophysics 1998, 357:299-309.
32. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:1977-1981.
33. Strohmeyer R., Ramirez M., Cole G.J., Mueller K., Rogers J. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. Journal of Neuroimmunology 2002, 131:135-146.
34. Thambisetty M., Hye A., Foy C., Daly E., Glover A., Cooper A., Simmons A., Murphy D., Lovestone S. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. Journal of Neurology 2008, 255:1712-1720.
35. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.O., Westman E., Kinsey A., Guntert A., Proitsi P., Powell J., Causevic M., Killick R., Lunnon K., Lynham S., Broadstock M., Choudhry F., Howlett D.R., Williams R.J., Sharp S.I., Mitchelmore C., Tunnard C., Leung R., Foy C., O'Brien D., Breen G., Furney S.J., Ward M., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Hodges A., Murphy D.G., Parkins S., Richardson J.C., Resnick S.M., Ferrucci L., Wong D.F., Zhou Y., Muehlboeck S., Evans A., Francis P.T., Spenger C., Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Archives of General Psychiatry 2010, 67:739-748.
36. Velazquez P., Cribbs D.H., Poulos T.L., Tenner A.J. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nature Medicine 1997, 3:77-79.
37. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000, 287:498-501.